Allogeneic Hematopoietic Cell Transplant for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Author(s) -
Nicole Davidson,
Hemalatha G. Rangarajan,
Kyla Driest,
Rajinder Bajwa,
Veronika Polishchuk,
Rolla AbuArja
Publication year - 2021
Publication title -
case reports in rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2090-6889
pISSN - 2090-6897
DOI - 10.1155/2021/9323141
Subject(s) - macrophage activation syndrome , medicine , serositis , hepatosplenomegaly , arthritis , rash , juvenile , immunology , tocilizumab , hematopoietic stem cell transplantation , disease , biology , genetics
Systemic juvenile idiopathic arthritis (sJIA) is characterized by arthritis, fever, rash, lymphadenopathy, hepatosplenomegaly, and serositis. Macrophage activation syndrome is the most feared complication of sJIA with a high risk of mortality. We report a 16-year-old female diagnosed with refractory systemic juvenile idiopathic arthritis (sJIA) complicated by recurrent macrophage activation syndrome (MAS), severe joint disease, and lung involvement requiring prolonged immunosuppressive therapy. She received a matched unrelated allogeneic hematopoietic cell transplant (Allo-HCT) using a reduced-intensity conditioning regimen and is now, 3 years after the transplant, with complete resolution of sJIA symptoms, off immunosuppressants, and with significant improvement in the quality of life.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom